Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Century Therapeutics (IPSC – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $4.05.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Cue Biopharma, and Moderna. According to TipRanks, Tenthoff has an average return of 2.0% and a 36.57% success rate on recommended stocks.
In addition to Piper Sandler, Century Therapeutics also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued today. However, yesterday, William Blair initiated coverage with a Hold rating on Century Therapeutics (NASDAQ: IPSC).
Based on Century Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $148 thousand and a GAAP net loss of $32.72 million. In comparison, last year the company earned a revenue of $2.22 million and had a GAAP net loss of $30.75 million
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IPSC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Century Therapeutics (IPSC) Company Description:
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
Read More on IPSC:
- Century Therapeutics Executes Strategic Acquisition and Equity Sales
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
- Century Therapeutics announces strategic pipeline expansion
- Century Therapeutics: Data from iPSC-derived cell therapy presented at AACR
- Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
